Cationic iridium complexes with chiral P,Nligands and tetrakis [3,5-(trifluoromethyl)phenyl]borate (BAr F ) as the counterion are efficient homogeneous catalysts for the enantioselective hydrogenation of olefins. The complexes are readily prepared, air-stable, and easy to handle. In contrast to chiral rhodium-and ruthenium-phosphine catalysts, they do not require the presence of a polar coordinating group near the C C bond. In the hydrogenation of unfunctionalized arylolefins, high enantioselectivities of > 95% ee with turnover numbers of up to 5000 and turnover frequencies of > 5000 h À1 have been achieved.
At low temperatures, the mononuclear copper(I) complex of the tetradentate tripodal aliphatic amine Me(6)tren (Me(6)tren = tris(2-dimethylaminoethyl)amine) [Cu(I)(Me(6)tren)(RCN)](+) first reversibly binds dioxygen to form a 1:1 Cu-O(2) species which further reacts reversibly with a second [Cu(I)(Me(6)tren)(RCN)](+) ion to form the dinuclear 2:1 Cu(2)O(2) adduct. The reaction can be observed using low temperature stopped-flow techniques. The copper superoxo complex as well as the peroxo complex were characterized by resonance Raman spectroscopy. The spectral characteristics and full kinetic and thermodynamic results for the reaction of [Cu(I)(Me(6)tren)(RCN)](+) with dioxygen are reported.
Iridium complexes derived from chiral P,N ligands are efficient catalysts for the enantioselective hydrogenation of 2-aryl-substituted terminal alkenes. Using 0.1 -1 mol % of catalyst at room temperature and ambient hydrogen pressure, high enantioselectivities (88 -94% ee), full conversions after short reaction times and essentially quantitative yields were obtained for a range of differently substituted 2-arylalkenes. Among six iridium complexes that were tested, the most selective catalyst was a complex with a phosphinite-oxazoline ligand derived from threonine (IrThrePHOX). In contrast to the hydrogenation of trisubstituted alkenes, a strong pressure effect was observed for this class of substrates. Lowering the hydrogen pressure from 50 to 1 bar resulted in a strong increase of the ee values.
Chiral iridium complexes with bicyclic pyridine-based N,P ligands have emerged as efficient catalysts for the enantioselective hydrogenation of unfunctionalized trialkyl-substituted olefins. Optimization of the reaction conditions by variation of the solvent, pressure, and temperature led to enantiomeric excesses of up to 99%. Three pure alkenes, (E)-2-cyclohexyl-2-butene and (E)- and (Z)-3,4-dimethyl-2-pentene were converted into the corresponding chiral alkanes with 97%, 94%, and 93% ee, respectively. Hydrogenation of the three C=C bonds of both α- and γ-tocotrienyl acetate led to α- and γ-tocopheryl acetate with very high diastereoselectivity. The same catalysts were successfully applied in the hydrogenation of trisubstituted alkenes with a carboxylic ester or a keto group in the γ position. This reaction was used as a key step in a highly enantioselective synthesis of the pheromone of the caddisfly Hesperophylax occidentalis. The hydrogenation of a structurally analogous allylic alcohol also gave high enantioselectivities.
Enantioselective conjugate reduction of a wide range of α,β-unsaturated carboxylic esters was achieved using chiral Ir N,P complexes as hydrogenation catalysts. Depending on the substitution pattern of the substrate, different ligands perform best. α,β-Unsaturated carboxylic esters substituted at the α position are less problematic substrates than originally anticipated and in some cases α-substituted substrates actually reacted with higher enantioselectivity than their β-substituted analogues. The resulting saturated esters with a stereogenic center in the α or β position were obtained in high enantiomeric purity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.